Table 2 Hazard ratios for all-cause and colorectal cancer-specific death and 95% confidence intervals in relation to stromal eosinophil scorea in the colorectal cancer patients, Iowa Women’s Health Study.

From: Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study

Stromal eosinophil score

1

>1–2

>2–3

>3

P-trend

All-cause death

Five-year follow-up

     

No. of deaths (n=172)

41

74

34

23

 

Person-years

254

587

445

358

 

HR (95% CI)b

Reference

0.83 (0.56–1.21)

0.51 (0.32–1.21)

0.44 (0.26–0.73)

0.0001

HR (95% CI)c

Reference

0.97 (0.65–1.44)

0.68 (0.42–1.08)

0.61 (0.36–1.02)

0.02

HR (95% CI)d

Reference

0.97 (0.65–1.44)

0.77 (0.47–1.25)

0.69 (0.40–1.19)

0.11

Total follow-upe

     

No. of deaths (n=299)

56

123

72

48

 

Person-years

523

1267

998

892

 

HR (95% CI)b

Reference

0.99 (0.72–1.36)

0.74 (0.52–1.05)

0.59 (0.40–0.87)

0.0009

HR (95% CI)c

Reference

1.08 (0.78–1.50)

0.88 (0.61–1.27)

0.72 (0.48–1.08)

0.04

HR (95% CI)d

Reference

1.07 (0.77–1.50)

0.95 (0.65–1.38)

0.79 (0.52–1.20)

0.18

Colorectal cancer death

Five-year follow-up

     

No. deaths (n=121)

30

53

25

13

 

Person-years

254

587

445

358

 

HR (95% CI)b

Reference

0.77 (0.49–1.21)

0.49 (0.29–0.84)

0.32 (0.17–0.62)

<.0001

HR (95% CI)c

Reference

0.96 (0.60–1.52)

0.70 (0.41–1.22)

0.48 (0.24–0.93)

0.01

HR (95% CI)d

Reference

0.97 (0.61–1.55)

0.84 (0.47–1.49)

0.57 (0.29–1.15)

0.11

 Total follow-up e

     

No. of deaths (n=138)

30

61

29

18

 

Person-years

523

1267

998

892

 

HR (95% CI)b

Reference

0.88 (0.57–1.37)

0.56 (0.34–0.94)

0.43 (0.24–0.77)

0.0005

HR (95% CI)c

Reference

1.05 (0.67–1.64)

0.76 (0.45–1.29)

0.61 (0.34–1.12)

0.04

HR (95% CI)d

Reference

1.07 (0.68–1.68)

0.92 (0.53–1.59)

0.75 (0.40–1.41)

0.31

  1. aStromal eosinophil score was assessed in stromal area of tumor.
  2. bModel 1: Adjusted for age.
  3. cModel 2: Model 1+BMI, smoking status, stage, and grade at diagnosis.
  4. dModel 3: Model 2+cytotoxic T-cell (also called CD8+) score.
  5. eTotal follow-up lasted from the date of diagnosis until death or the end of this study in 2011.